Indian firms may garner up to 50% of USFDA nod share in 2023
NEW DELHI: Indian companies are expected to secure a 48-50 percent share of approvals for new drugs from the US ...
NEW DELHI: Indian companies are expected to secure a 48-50 percent share of approvals for new drugs from the US ...
Blitz Bureau NEW DELHI: The sowing gap has narrowed from a quarter to a twentieth in five weeks. That is...
Read moreDetails